Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 17, 2006 Brian Lawler	Lilly Doesn't Like Sharing Profits The company is buying out ICOS Corporation, its partner in erectile-dysfunction drug Cialis. Investors, take note.
The Motley Fool July 13, 2004 Brian Gorman	The "Cialis Promise" Eli Lilly and Icos are offering a free trial of their drug Cialis for men who have never used it before and promise that participants not pleased with the results will receive a voucher for a competing product.
The Motley Fool January 10, 2008 Brian Orelli	Good News for Lucky Men Eli Lilly's erectile dysfunction drug can now be taken daily.
The Motley Fool October 20, 2006 Brian Lawler	Lilly Pads Its Earnings Lilly reports third-quarter 2006 numbers and gobbles up Cialis. Investors, take note.
The Motley Fool November 24, 2010 Brian Orelli	A Manly FDA Approval Eli Lilly has something to be thankful for this week; the Food and Drug Administration approved Axiron, its testosterone replacement therapy.
The Motley Fool May 27, 2005 Nick Baker	Mama Always Said You'd Go Blind Urban legends aside, what do new concerns about Viagra and Cialis mean for investors?
The Motley Fool April 20, 2004 Alyce Lomax	Pfizer's Fight First-quarter earnings give mixed messages on the drug maker's meds.
BusinessWeek October 27, 2003 Michael Arndt	Is Viagra Vulnerable? Eli Lilly's Cialis lasts for 36 hours -- and a $100 million ad blitz will spread the word.
BusinessWeek February 28, 2005 David Kiley	The Little Blue Pill -- And Pals -- Have The Blues Despite gargantuan ad budgets, sales are trailing expectations for all three erectile dysfunction contenders.
The Motley Fool October 22, 2007 Brian Orelli	New Warnings Won't Sink ED Drug Sales Shockingly, new safety warnings won't hurt erectile dysfunction drugs. Any investor jumpiness should be looked at as a buying opportunity for smart investors.
The Motley Fool January 27, 2011 Rich Smith	What's Behind the Run-Up at Rexahn? The pharmaceutical's hot streak could soon burn up all its cash.
The Motley Fool April 17, 2007 Ryan Fuhrmann	Clean Bill of Health at Eli Lilly Lilly recorded another solid quarter, but its valuation is a little rich.
The Motley Fool July 10, 2008 Brian Lawler	Lilly Targets a Tiny Prize As drugmakers go, this acquisition's a value meal.
The Motley Fool January 5, 2004 Alyce Lomax	Side Effects at Lilly? Growing profits, with earnings pains.
The Motley Fool August 16, 2011 Brian Orelli	Keeping Those Little Blue Pill Sales Up Pfizer wins a patent lawsuit for Viagra.
The Motley Fool February 17, 2005 Karl Thiel	Sleeping on Neurocrine's Shares Why haven't Neurocrine Biosciences shares moved? It's partly history, with delays in getting an insomnia drug to market.
The Motley Fool October 22, 2007 Brian Lawler	Modest Numbers From Eli Lilly Its sales were up for the quarter, but a new drug might be the best indicator of its prospects. Lilly's pipeline will dictate its near-term future.
The Motley Fool January 31, 2007 Brian Lawler	Lilly Floats Atop Rivals The large-cap pharma posts slow, steady growth. Investors, take note.
The Motley Fool January 28, 2011 Brian Orelli	Avoid This Falling Knife for Now 2011 could be just the start of a long slide for Lilly. And 2012 will see difficult year-over-year comparison.
The Motley Fool March 23, 2011 Brian Orelli	Eli Lilly: Great Plan, Poor Execution Eli Lilly shuns large mergers, but hasn't produced drugs on its own.
The Motley Fool May 24, 2011 Brian Orelli	If at First You Don't Succeed, Spin It Off Eli Lilly ditches Xigris by spinning off BioCritica.
The Motley Fool November 21, 2008 Brian Orelli	Viagra Stays Behind the Counter All puns about soft sales and wishing something would go up in this market have been removed from this article.
The Motley Fool May 18, 2010 Brian Orelli	What Astellas' Purchase of OSI Means for Biotech Investors Stop buying for the potential takeout.
The Motley Fool November 5, 2010 Brian Orelli	Better Late Than Never for Cymbalta Eli Lilly gets an expanded approval for Cymbalta.
The Motley Fool May 31, 2007 Brian Lawler	Dueling Fools: Eli Lilly Bear Rebuttal Shareholders who buy into Lilly at its current valuation just won't have the same opportunity for stock price appreciation as those who bought shares in the late '80s or early '90s.
The Motley Fool August 13, 2010 Brian Orelli	Already a Slippery Slope for Eli Lilly The company gets a whiff of what its patent cliff might be like.
The Motley Fool January 28, 2010 Brian Orelli	The Biggest Development-Stage Drugmaker, Ever Eli Lilly seems to have a lot more in common with its development-stage little brothers than it does with its big pharma brethren.
The Motley Fool December 24, 2007 Rick Aristotle Munarriz	4 Stocks That Took a Hike These stocks recently raised their dividends: Pfizer... Eli Lilly... Moody's... Waste Management...
The Motley Fool July 23, 2010 Brian Orelli	Eli Lilly Looks Great Today, but I'm Concerned About Tomorrow Eli Lilly is firing on all cylinders, but is there a blowout in its future?
The Motley Fool October 21, 2004 Roger Nusbaum	Pictures of Lilly Eli Lilly's numbers get lost in the wake of Merck and Pfizer. While the market waits for drug stocks to recover, investors can collect Lilly's 2.5%, safe, dividend.
The Motley Fool July 26, 2007 Brian Lawler	Lilly Doesn't Wilt The second quarter was another good one for Eli Lilly. Top-line and bottom-line both grew.
The Motley Fool October 21, 2010 Brian Orelli	Nice Earnings, Eli Lilly, but ... Eli Lilly trounced analysts' earnings estimates today, but investors sighed -- and for good reason.
The Motley Fool February 29, 2008 Brian Orelli	2007 Pharma Roundup How did big pharma do in 2007? With the drug sector earnings season winding down, now seems like a good time to take a look at how they fared and, more importantly, where they're headed.
Bio-IT World February 11, 2005 Malorye A. Branca	Catching a Big Pharma Partner Deal flow: biotechs learn to squeeze value out of hot product deals when choosing a suitor.
The Motley Fool May 26, 2009 Brian Orelli	Will the FDA Approve These Drugs? Plenty of Prescription Drug User Fee Act dates are right around the corner. Read on to see which pharma companies may be affected.
The Motley Fool November 18, 2009 Brian Orelli	VIVUS Gets a Spark A new erectile-dysfunction drug shows promise.
The Motley Fool March 24, 2005 Brian Gorman	Eli Lilly Turns to Japan The company's move to focus more resources on Japan makes good sense.
The Motley Fool December 12, 2008 Brian Orelli	A Long-Term Play for Your Port Long-term prospects look better than the near term ones for Eli Lilly and its investors.
The Motley Fool December 10, 2009 Brian Orelli	A Tale of Two Lillys It was the best of times, it was the worst of times. Dickens could have been talking about Eli Lilly which has a tale of two cities all on its own.
The Motley Fool November 9, 2010 Brian Orelli	Forget R&D; Buy Your Way Into Diagnostics Eli Lilly is expanding its diagnostics business by picking up privately held Avid Radiopharmaceuticals.
The Motley Fool August 17, 2007 Brian Lawler	The Perfect Pharma Acquisition The pharmaceutical industry has been busy consolidating in the past year. With so much buying and selling going on, here is speculation on what would constitute the perfect pharma acquisition.
The Motley Fool May 31, 2007 Brian Lawler	Dueling Fools: Eli Lilly Bear Well-managed companies don't always make for good investments. This pharmaceutical powerhouse is a good example.
The Motley Fool August 4, 2010 Ryan McBride	How Eli Lilly Let a Billion-Dollar Molecule Slip Away, and Make a Fortune for Vertex The remains of Lilly's partnership with Vertex Pharmaceuticals.
The Motley Fool June 30, 2010 Rich Smith	This Just In: Upgrades and Downgrades Major Wall Street investment house Soleil Securities downgraded Eli Lilly shares to "sell."
The Motley Fool December 26, 2006 Rick Aristotle Munarriz	4 Stocks That Took a Hike Companies with growing yields can make you rich in more ways than the obvious. State Street... Pfizer... Eli Lilly... The Andersons...
The Motley Fool August 20, 2010 Brian Orelli	Depression Is Painful. Advisory Panels More So. Eli Lilly's Cymbalta has a rough time in from of the panel of experts.
The Motley Fool March 27, 2008 Brian Lawler	Eli Lilly Hands Over Cold Cash Lilly loses to the state of Alaska in a courtroom battle over its top drug Zyprexa.
The Motley Fool June 14, 2004 Brian Gorman	Elan Teams Up With Lilly The companies' manufacturing agreement may be more of a positive sign for Eli Lilly than it is for Elan.
The Motley Fool December 14, 2010 Brian Orelli	Another Mishap for a Drugmaker That Can't Afford It Eli Lilly puts cancer drug tasisulam on a clinical hold.
The Motley Fool May 20, 2009 Brian Orelli	Joining to Treat, and Beat, Diabetes Medical-device maker Medtronic and drugmaker Eli Lilly are teaming up to co-promote the companies' diabetes products to doctors and patients.